Quick answers
- What is Crexont?
- Crexont is a brand name of Carbidopa and levodopa, a prescription medicine. The FDA NDC Directory lists 4 Crexont products in 4 strengths and forms.
- Who makes Crexont?
- Impax holds the FDA application for Crexont (NDA217186, approved August 7, 2024).
- Is there a generic or store brand of Crexont?
- Other products of Carbidopa and levodopa are listed with the FDA, but none in exactly the same strength and form as a Crexont product.
- What do pharmacies pay for Crexont?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 4 Crexont strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Crexont been recalled?
- No recall linked to Crexont products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Crexont is
Each Crexont product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Carbidopa and levodopa · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| carbidopa hydrate 35 mg · levodopa 140 mg capsule, extended release (oral) | Crexont | None listed | DailyMed |
| carbidopa hydrate 52.5 mg · levodopa 210 mg capsule, extended release (oral) | Crexont | None listed | DailyMed |
| carbidopa hydrate 70 mg · levodopa 280 mg capsule, extended release (oral) | Crexont | None listed | DailyMed |
| carbidopa hydrate 87.5 mg · levodopa 350 mg capsule, extended release (oral) | Crexont | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Carbidopa and levodopa →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA217186 | Impax | August 7, 2024 | 4 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| carbidopa hydrate 35 mg · levodopa 140 mg capsule, extended release | Brand: Crexont | $4.59 per capsule |
| carbidopa hydrate 52.5 mg · levodopa 210 mg capsule, extended release | Brand: Crexont | $4.58 per capsule |
| carbidopa hydrate 70 mg · levodopa 280 mg capsule, extended release | Brand: Crexont | $4.58 per capsule |
| carbidopa hydrate 87.5 mg · levodopa 350 mg capsule, extended release | Brand: Crexont | $4.58 per capsule |
NADAC list of November 4, 2026; these prices took effect on July 1, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Crexont
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Crexont products.
- Amneal Pharmaceuticals LLC4 products
Recalls
No recall linked to Crexont products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.